Low Interleukin 10 Production at Birth Is a Risk Factor for Atopic Dermatitis in Neonates with Bifidobacterium Colonization

2018 ◽  
Vol 177 (4) ◽  
pp. 342-349 ◽  
Author(s):  
Shuichi Suzuki ◽  
Eduardo Campos-Alberto ◽  
Yoshinori Morita ◽  
Makoto Yamaguchi ◽  
Takayuki Toshimitsu ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Risk Factor ◽  
Interleukin 10

The interleukin-10 promoter haplotype ATA is a putative risk factor for aggressive periodontitis

2007 ◽  
Vol 0 (0) ◽  
pp. 070521022335002-??? ◽  
Author(s):  
S. Reichert ◽  
H. K. G. Machulla ◽  
J. Klapproth ◽  
U. Zimmermann ◽  
Y. Reichert ◽  
...  
Keyword(s):  
Risk Factor ◽  
Aggressive Periodontitis ◽  
Interleukin 10 ◽  
Putative Risk Factor ◽  
Promoter Haplotype

Interleukin-10 haplotype associated with total serum IgE in atopic dermatitis patients

Allergy ◽  
2005 ◽  
Vol 60 (9) ◽  
pp. 1146-1151 ◽  
Author(s):  
H. D. Shin ◽  
B. L. Park ◽  
L. H. Kim ◽  
J.-S. Kim ◽  
J.-W. Kim
Keyword(s):  
Atopic Dermatitis ◽  
Interleukin 10 ◽  
Total Serum ◽  
Serum Ige

scholarly journals Contact allergy to Compositae plants in patients with atopic dermatitis

2004 ◽  
Vol 57 (5-6) ◽  
pp. 209-218 ◽  
Author(s):  
Marina Jovanovic ◽  
Mirjana Poljacki ◽  
Verica Djuran ◽  
Ljuba Vujanovic ◽  
Ruza Sente ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Risk Factor ◽  
Sesquiterpene Lactone ◽  
Detection Rate ◽  
Contact Allergy ◽  
Achillea Millefolium ◽  
Tanacetum Vulgare ◽  
Arnica Montana ◽  
Tanacetum Parthenium ◽  
Compositae Plants

To investigate the frequency of Compositae sensitivity is one of the most important goals of current dermatology and allergology. We have patch tested 30 adult patients suffering from ?extrinsic? atopic dermatitis with sesquiterpene lactone mix and Compositae mix including Compositae mix individual ingredients, extracts of arnica (Arnica montana), chamomile (Chamomilla recutita), tansy (Tanacetum vulgare), feverfew (Tanacetum parthenium) and yarrow (Achillea millefolium) as well as with specific series for patients with atopic dermatitis. All allergens were purchased from Hermal-Trolab (Reinbek, Germany). There were 6 (20%) patients positive to Compositae mix only, and 3 (10%) patients positive to both Compositae mix and sesquiterpene lactone mix. Among 9 Compositae mix-sensitive patients 8 (88.8%) were positive to at least 1 of its individual ingredients: 5 (55.5%) to chamomile, 4 (44.4%) to arnica, 2 (22.2%) to tansy, and 2 (22.2%) to feverfew. Among Compositae-sensitive patients 78.8% had other contact allergies, most often to nickel (33.3%). Since our study represents the first report on contact allergy to Compositae among patients with "extrinsic" type of atopic dermatitis, it substantiates the statement that atopy represents a risk factor for Compositae allergy. In conclusion, the overall prevalence of 30% Compositae-sensitive among patients with ?extrinsic? atopic dermatitis detected in our study represents a basal sesquiterpene lactone mix detection rate of 10%, reinforced and safely supplemented by 20% by testing with the Compositae mix.

scholarly journals PERSISTENT SUBCLINICAL INFLAMMATION IN THE SKIN AS A RISK FACTOR FOR RELAPSE IN ATOPIC DERMATITIS: FROM PATHOPHYSIOLOGY TO TREATMENT

2017 ◽  
Vol 14 (4-5) ◽  
pp. 108-119
Author(s):  
O V Kalyuzhin
Keyword(s):  
Atopic Dermatitis ◽  
Risk Factor ◽  
Chronic Inflammation ◽  
Calcineurin Inhibitors ◽  
Skin Inflammation ◽  
Subclinical Inflammation ◽  
Cutaneous Inflammation ◽  
Antiinflammatory Therapy ◽  
Topical Calcineurin Inhibitors ◽  
Increased Risk

Lowgrade cutaneous inflammation, which persists after induction of remission of atopic dermatitis (AD), determines the risk of repeated relapses and progression of the disease. It has been well established that subclinical inflammation in the skin of atopic patients may be inhibited by topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), and proactive courses of these drugs prolong remission of the disease. In terms of prolonged application, TCI have some advantages over TCS in the context of safety. However, the routine use of TCI in AD is constrained by many practitioners who do not accept the concept of subclinical chronic inflammation and the strategy of maintenance antiinflammatory therapy on areas prone to repeated relapses, as well as obsolete myths about the association of TCI application with increased risk of cutaneous lymphoma. The review presents modem data on the pathophysiology of AD with a focus on subclinical skin inflammation, which persists after regression of acute manifestations of the disease, and the possibilities of suppressing this inflammation with TCI. Data on the safety of TCI for longterm use and the absence of prooncogenic potential are given. In addition, the relevance and expediency of pimecrolimus use in children under 2 years of age are emphasized.

Sign in / Sign up

Export Citation Format

Share Document